0 reactions
indianmarketgrid The STOXX 600 fell 0.6% while Novartis dropped after a second late-stage trial setback for del-desiran.
READ FULL ANALYSIS MEMBER ANALYSIS
THE IMG COMMUNITY
Market insights. Fresh perspectives. Your conversation.
indianmarketgrid The STOXX 600 fell 0.6% while Novartis dropped after a second late-stage trial setback for del-desiran.